To include your compound in the COVID-19 Resource Center, submit it here.

VivaGel: Phase II data

Data from the modified intent-to-treat (mITT) population (n=111) of a double-blind, U.S. Phase II trial in 132 patients showed that once-daily 0.5%, 1% and 3% topical

Read the full 260 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE